SCHEMBL17238588

SCHEMBL17238588

N#Cc1c(F)cc(NC(=O)O)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 1/20 0.42
▸ TAS1R3 Q7RTX0 1/20 0.39
▸ TAS1R1 Q7RTX1 1/20 0.39
▸ TAS1R2 Q8TE23 1/20 0.39
▸ NPC1 O15118 5/20 0.38
▸ RAB9A P51151 5/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ SLC2A1 P11166 1/20 0.37
▸ GPR35 Q9HC97 2/20 0.37
▸ TSHR P16473 1/20 0.36
▸ THRA P10827 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ TRPV4 Q9HBA0 1/20 0.35
▸ FABP4 P15090 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29177276 0.82 KMT2A (0.39) NPC1RAB9ASMN1; SMN2MEN1LMNA
SCHEMBL23140326 0.79 EGLN2 (0.44) ENPP2HTT
SCHEMBL16237339 0.78 KMT2A (0.42) NPC1RAB9ASMN1; SMN2MEN1LMNA
SCHEMBL23537568 0.75 NPC1 (0.42) ENPP2NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL19778549 0.73 LMNA (0.47) RAB9ASMN1; SMN2MEN1LMNAKMT2A
SCHEMBL21568213 0.73 ALDH1A1 (0.46) ENPP2NPC1MEN1LMNAKMT2A
SCHEMBL26087466 0.72 THRA (0.42) LMNAKMT2AGPR35THRATHRB
SCHEMBL29177259 0.72 GPR35 (0.43) NPC1RAB9ASMN1; SMN2MEN1LMNA
SCHEMBL2091322 0.70 EGFR (0.51) ENPP2NPC1RAB9AKMT2AGPR35
SCHEMBL2097418 0.70 THRA (0.44) NPC1RAB9ASMN1; SMN2MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 — — US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 ENPP2 1157/4885TAS1R3 2428/4885TAS1R1 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback